Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
NCT03100253 · Mario Negri Institute for Pharmacological Research · PHASE4 · terminated · last registry update 2022-09-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow recrutiment” | – | Registry record, Mario Negri Institute for Pharmacological Research |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-09-15Also stopped (withdrawn): Alonso Vera Torres, Analogs, Prostaglandin E1 + Standard therapeutic protocol (NCT04536363)
- 2023-09-14Phase 3 first posted: Centre Hospitalier Universitaire Dijon, Tocilizumab treatment + Blood samples (NCT06037460)
- 2023-08-15Also stopped (withdrawn): University of Nebraska, Tocilizumab + Ranibizumab (NCT02511067)
- 2023-08-14Phase 3 first posted: Hoffmann-La Roche, Satralizumab + Placebo (NCT05987423)
- 2023-08-04Also stopped (terminated): Hoffmann-La Roche, RO7444973 + Tocilizumab (NCT05129280)
- 2023-07-27Phase 3 first posted: Assiut University, Rituximab + IL6 inhibitor (NCT05963048)
- 2023-07-17Results posted on the registry: GlaxoSmithKline, GSK3196165 (Otilimab) + Sarilumab (NCT04134728)
- 2023-06-05Results posted on the registry: Memorial Sloan Kettering Cancer Center, Tocilizumab (NCT04377659)
- 2023-04-19Results posted on the registry: Medical College of Wisconsin, Tacrolimus + Methotrexate (NCT03699631)
- 2023-04-05Phase 3 first posted: Biocad, Levilimab (NCT05800327)
- 2023-03-14Results posted on the registry: University Hospital, Ghent, Anakinra + Siltuximab (NCT04330638)
- 2023-03-09Results posted on the registry: William R. Drobyski, MD, Tacrolimus + Methotrexate (NCT02206035)
- 2023-02-13Phase 3 first posted: Celltrion, CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab) (NCT05725434)
- 2023-02-08Phase 3 first posted: Tang-Du Hospital, Tocilizumab Injection (NCT05716035)
- 2023-02-03Also stopped (withdrawn): ASST Fatebenefratelli Sacco, Sarilumab Prefilled Syringe (NCT04386239)
- 2023-01-25Also stopped (terminated): University of Southern Denmark, Tocilizumab + Sarilumab (NCT04842981)
- 2022-12-02Results posted on the registry: Massachusetts General Hospital, Tocilizumab + Prednisone (NCT03726749)
- 2022-11-08Phase 3 first posted: AbbVie, Upadacitinib + Tocilizumab (NCT05609630)
- 2022-10-24Results posted on the registry: Fresenius Kabi SwissBioSim GmbH, MSB11456 + EU-approved RoActemra (NCT04512001)
- 2022-10-10Results posted on the registry: Westyn Branch-Elliman, SARILUMAB (NCT04359901)
- 2022-09-10Phase 3 first posted: Wei-Che Ko, Squaric Acid Dibutyl Ester + Dupilumab (NCT05535738)
- 2022-08-16Phase 3 first posted: Hoffmann-La Roche, Satralizumab (NCT05503264)
- 2022-08-05Phase 3 first posted: Celltrion, CT-P47 + EU-approved RoActemra (NCT05489224)
- 2022-06-21Also stopped (terminated): MedSIR, Tocilizumab + Pembrolizumab (MK-3475) (NCT04335305)
- 2022-06-10Results posted on the registry: Sanofi, Sarilumab SAR153191 (REGN88) + Sarilumab-matching placebo (NCT03600818)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision